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Advanced therapies are increasingly demanded by patients with the intent of treating some
incurable conditions. Because family medicine professionals play an important role as
health educators, their residency programs should incorporate new knowledge related
to advanced therapies. To successfully implement these programs, how family medicine
residents perceive these therapies should be investigated. The main components of percep-
tion, i.e. conceptual, procedural and attitudinal, refer to knowledge, skills and feelings,
respectively.
Methods and findings
We designed a specific questionnaire to assess the components of perceptions of advanced
therapies in 300 medical residents enrolled in the Spanish National Family Medicine Resi-
dency Program. Each component consisted of 4 or 5 topics and each topic contained 6
items. Respondents scored highest in the procedural component (average 4.12±1.00), fol-
lowed by the attitudinal (3.94±1.07) and conceptual component (3.04±1.43). Differences
among the three components were statistically significant (p<0.00017). Family medicine
residents perceived that procedures to implement advanced therapies are well established,
especially their application. However, they felt their cognitive background was insufficient to
respond efficiently to the expectations generated by these new therapeutic tools, especially
in the regulatory framework. High awareness of the risks and limitations of these treatments
was reflected by residents’ preference for clinically tested therapies. Although they appropri-
ately situated treatment with these therapies within hospital care, they associated the bio-
fabrication of novel products with research centers, although these therapeutic tools can be
produced in different facilities.
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Conclusions
These results are potentially useful for designing future training programs and health poli-
cies for family medicine residents, and suggest the need to implement specific training pro-
grams in advanced therapies at the conceptual, procedural and attitudinal level.
Introduction
In recent decades, genes, cells and tissues have been adapted as new therapeutic tools in medi-
cine. In this new approach, known as advanced therapies, each of these therapeutic agents is
termed an advanced therapy medicinal product (ATMP) [1]. As in other medicinal products
such as drugs, devices and biological agents, products based on genes, cells and tissues are sub-
ject to regulatory requirements that vary widely among countries and product types [2]. The
regulatory requirements for ATMPs were established in the European Union by two European
Directives (2003/63/EC and 2009/120/EC) and by EC Regulation No. 1394/2007 of the Euro-
pean Parliament and Council. Specific regulations have also been established in different coun-
tries, e.g. FDA regulation in the USA [3]. In European countries, marketing authorization
must follow a centralized procedure at the European Medicines Agency (EMA), and very pre-
cise guidelines must be met for product safety, control of the manufacturing process, and clini-
cal trials [1].
Although these therapies may have great potential, their results thus far have not advanced
as much as initially foreseen [4]. Although some scientifically- and clinically-proven gene,
stem-cell and artificial tissue-based interventions are being successfully applied, unproven
interventions with these therapies are also being sought and used by patients with the intent of
treating some degenerative or incurable conditions [5, 6].The consequence is a growing inter-
national market in this field, with clinics around the world offering unproven and unapproved
cell and tissue therapies for a vast array of conditions without evidence of safety or efficacy for
these products. This phenomenon, generally known as ‘‘stem cell tourism”, is a subject of great
debate and concern [7–10].
Among the concerns associated with the stem cell tourism market are physical and financial
risks for patient and reputational risks for legitimate research on and clinical applications of
advanced therapies [5, 11]. A further financial aspect with future implications is when patients
return from receiving unproven and unapproved treatments in the private market and then
demand follow-up care in publicly funded medical systems [5, 12]. As pointed out by Gunter
and colleagues [9], patients need to be equipped to understand the difference between (a) for-
mal clinical trials and the innovative practice of medicine (where their rights are protected and
risks are controlled and communicated) and (b) fraudulent cell and tissue therapy practices
(where there is no protection or demonstration of competency, and misinformation is the
rule).
In this context, health education plays a fundamental role not only as an instrument for
information and health promotion, but also as a necessary mechanism to guide patients
towards the best choice, and thus to contribute to the sustainability of the health system. This
is important because of the high costs involved in the implementation of advanced therapy
programs in health systems [13]. The role of family medicine physicians in this educational
process is highly relevant because they are the basic agents in the interrelation between patients
and the health systems in all aspects related to scientific knowledge and their clinical condition.
As has been clearly established, family medicine physicians must use data to monitor and
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manage their patient population, and use well-established science and knowledge to prioritize
the clinical services that are most likely to benefit patient health. In addition, patients also
expect their family medicine physician to help them prevent, understand and manage their
diseases [14].
To equip family medicine physicians to carry out these activities, and therefore to prevent
the potential risks of stem cell tourism, residency training programs should incorporate new
knowledge and evidence related to advanced therapies, not only regarding the conceptual and
procedural components of ATMPs, but also regarding physicians’ attitudinal approach.
In the present study we investigate different components of perception (e.g. conceptual,
procedural and attitudinal) in family medicine residents in Spain in order to determine the
variables or constructs which could serve as a foundation for their future learning processes in
advanced therapies [15, 16]. These variables or constructs can be defined as the way in which
students conceptualize and relate to the learning process, which is assumed to affect their
learning and achievements [17]. Insights into residents’ perceptions will help us to understand
their constructs, especially concerning their expectations with regard to the tasks they should
learn about and become skilled in. The research reported here was designed to answer to the
following question: what are the conceptual, procedural and attitudinal components perceived
by family medicine residents regarding treatment with advanced therapies? The results are




The present study was carried out at 20 hospitals and health centers operated by the Public
Andalusian Health System (Servicio Andaluz de Salud) and accredited as training centers for
family medicine residents. A total of 323 medical residents enrolled in the National Family
Medicine Residency Program were invited to participate in the study, whose participation was
voluntary. Altogether, 300 (92.9%) of the residents contacted agreed to be included in the
study. Average age of the participants was 28.16±4.94 years. Slightly more than one fourth of
the participants (84, 28%) were men (average age 28.81±6.11 years) and 216 (72%) were
women (average age 27.91±4.38); these numbers are representative of the whole population of
family medicine residents in Spain.
All participants signed an informed consent form, and all results were analyzed anony-
mously. The study and the protocol were approved by the Ethics and Research Committee of
the University of Granada (ref. 62/CEIH/2016).
Instrument
To evaluate family medicine residents’ perceptions regarding advanced therapies, we designed
a specific questionnaire to solicit information on conceptual, procedural and attitudinal com-
ponents. The conceptual component refers to knowledge (as information recall and remem-
bering) of classifications and categories, principles and generalizations, theories, models and
structures [18]. The procedural component reflects knowledge of subject-specific skills and
algorithms, subject-specific techniques and methods, and criteria for determining when to use
appropriate procedures [18]. The attitudinal component refers to a set of emotions and feel-
ings experienced over time on a specific issue [19]. Each component consisted of 4 or 5 topics
and each topic contained 6 items (Table 1). Residents rated each item on a five-point Likert-
like scale: 1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree and
5 = strongly agree (S1 Table). The questionnaire was given to the residents along with a brief
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explanation on the purpose of the instrument and instructions about how to complete the
questionnaire.
The set of topics and items included in the questionnaire was initially selected by the
authors of the present work, who have a background in advanced therapies and family medi-
cine. To validate the questionnaire prior to its use, the instrument was critically analyzed by a
panel of national and international experts in the field. After that, a pilot study was carried out
in a group of 30 residents who volunteered to complete the questionnaire, and its internal con-
sistency and reliability were found to be very good (Cronbach’s alpha index of 0.9571). After
this preliminary process, the questionnaire was used for the whole study sample. Analysis of
the results obtained from 300 residents confirmed the validity of the preliminary results, as
determined by a Kaiser-Meyer-Olkin measure of sampling adequacy (KMO) value of 0.8939, a
Bartlett’s test of sphericity value of 0.0000, and a Cronbach’s alpha index of 0.9561.
Table 1. Items in the questionnaire corresponding to different components and topics. For each item, both the full question and its abbreviated item name are shown.
COMPONENT TOPIC ITEM ITEM
CONCEPTUAL Advanced therapies AdT1 Do you know what advanced therapies are?
AdT2 Are you familiar with the concept of gene therapy?
AdT3 Are you familiar with the concept of somatic cell therapy?
AdT4 Are you familiar with the concept of combined advanced therapy?
AdT5 Do you know if gene therapy is an advanced therapy?
AdT6 Do you know if tissue engineering is an advanced therapy?
Artificial tissues ArT1 Are you familiar with the concept of artificial tissue?
ArT2 Are you familiar with the concept of biomaterial?
ArT3 Are you familiar with the concept of growth factors?
ArT4 Do you distinguish conceptually between a natural tissue and an artificial one?
ArT5 Are you familiar with the concept of tissue engineering?
ArT6 Are you familiar with the concept of regenerative medicine?
Cell and tissue basis of the human body CTB1 Are you familiar with the concept of cell?
CTB2 Are you familiar with the concept of tissue?
CTB3 Are you familiar with the concept of stem cell?
CTB4 Are you familiar with the concept of embryonic stem cell?
CTB5 Are you familiar with the concept of adult stem cell?
CTB6 Are you familiar with the concept of IPS cell?
Novel medical products NMP1 Do you know if a cell can be considered a medicine?
NMP2 Do you know if a tissue can be considered a medicine?
NMP3 Do you know if transplanted organs are medicines?
NMP4 Do you know if biomaterials are used to treat diseases?
NMP5 Do you know if growth factors are used to treat diseases?
NMP6 Do you know if there are benefits of these therapies with respect to current treatment
techniques?
Regulatory framework RF1 Do you know if there is specific EU legislation for advanced therapies?
RF2 Do you know what GMP rooms are?
RF3 Do you know if it is mandatory to manufacture advanced therapy products considered
medicines in GMP rooms?
RF4 Do you know if it is mandatory to perform a clinical trial before using advanced therapy
products?
RF5 Do you know if all advanced therapies require authorization from the Spanish and European
agencies for their implementation?
RF6 Do you know if advanced therapies are in the service portfolio of the National Health
System?
(Continued)
Advanced therapies in family medicine
PLOS ONE | https://doi.org/10.1371/journal.pone.0214950 April 3, 2019 4 / 19
Table 1. (Continued)
COMPONENT TOPIC ITEM ITEM
PROCEDURAL Application and use of advanced therapies AUAT1 Would you use the patient’s own cells for treatment with cell therapy?
AUAT2 Would you use cells from donors to treat a patient with cell therapy?
AUAT3 Would you apply cell therapy to treat a disease?
AUAT4 Would you apply gene therapy to treat a disease?
AUAT5 Would you apply tissue-engineered tissues to treat a disease?
AUAT6 Would you apply artificial tissues built with cells, biomaterials and growth factors together
to treat a disease?
Application center for advanced therapies ACAT1 Would you use hospitals for a cell therapy treatment?
ACAT2 Would you use primary care health centers to monitor patients treated with cell therapy?
ACAT3 Would you use hospitals for a gene therapy treatment?
ACAT4 Would you use primary care health centers to follow up patients treated with gene therapy?
ACAT5 Would you use hospitals to treat a patient with artificial tissues generated by tissue
engineering?
ACAT6 Would you use primary care health centers to monitor patients treated with artificial tissues
generated by tissue engineering?
Biofabrication components for advanced
therapies
BCAT1 Would you use umbilical cord stem cells to build artificial tissues?
BCAT2 Would you use bone marrow stem cells to build artificial tissues?
BCAT3 Would you use adipose tissue stem cells to build artificial tissues?
BCAT4 Would you use dental pulp stem cells to build artificial tissues?
BCAT5 Would you build artificial tissues with biomaterials?
BCAT6 Would you build artificial tissues with growth factors?
Centers for biofabrication and storage of
advanced therapies
CBSAT1 Would you store artificial tissues in tissue banks for deferred use?
CBSAT2 Would you store cells in tissue banks for deferred use?
CBSAT3 Would you store genes in tissue banks for deferred use?
CBSAT4 Would you use a primary care health center to build artificial tissues?
CBSAT5 Would you use a pharmaceutical company to build artificial tissues?
CBSAT6 Would you use a research center to build artificial tissues?
ATTITUDINAL Research interest in advanced therapies RIAT1 Are you interested in cell therapy research?
RIAT2 Are you interested in gene therapy research?
RIAT3 Are you interested in artificial tissue therapy research?
RIAT4 Do you think clinical trials in cell therapy are a good idea?
RIAT5 Do you think clinical trials with artificial tissues are a good idea?
RIAT6 Do you think clinical trials in gene therapy are a good idea?
Research interest in classical therapies RICT1 Are you interested in research in surgery?
RICT2 Are you interested in pharmacotherapy research?
RICT3 Are you interested in research in physical medicine and physiotherapy?
RICT4 Are you interested in psychotherapy research?
RICT5 Do you think clinical trials to test pharmaceutical drugs are a good idea?
RICT6 Do you think clinical trials in physical therapy are a good idea?
Valuation of centers for advanced therapies VCAT1 Do you prefer hospitals for the application of cell therapy?
VCAT2 Do you prefer hospitals for the application of gene therapy?
VCAT3 Do you prefer hospitals for the application of artificial tissue therapy?
VCAT4 Do you prefer hospitals for the application of combined advanced therapies?
VCAT5 Do you prefer artificial tissues to be manufactured in hospitals?
VCAT6 Do you prefer artificial tissues to be manufactured by the pharmaceutical industry?
Valuation of treatment with advanced
therapies
VTAT1 Do you think cell therapy is a good idea?
VTAT2 Do you think gene therapy is a good idea?
VTAT3 Do you think therapy with artificial tissues is a good idea?
VTAT4 Do you think so-called advanced therapies is a good idea?
VTAT5 Do you think therapy with physical medicine is a good idea?
VTAT6 Do you think pharmaceutical drug therapy is a good idea?
https://doi.org/10.1371/journal.pone.0214950.t001
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Statistical analysis
Average values and standard deviations were calculated for each item, for each topic and for
each component for male and female residents separately and for the entire sample together.
To identify statistically significant differences between groups, we used ANOVA. This analysis
was used to carry out pairwise comparisons of the following groups: 1) components of percep-
tion, 2) topics within the same component, 3) items within the same topic, 4) male and female
residents. All statistical analyses were two-tailed. To correct for multiple testing, a Bonferroni-
adjusted p value below 0.00017 was considered statistically significant.
Results
The results for each component, topic and item are summarized in Tables 2, 3 and 4 and raw
data are available in the S1 File.
First, we analyzed the results for the three components evaluated in the questionnaire.
Comparisons across the different components showed that the highest scores appeared in the
procedural component (average 4.12±1.00), followed by the attitudinal component (3.94
±1.07) and the conceptual component (3.04±1.43). Averages and standard deviations are
shown in Tables 2–4 and Fig 1A. Tables 2–4 show the statistical p values for the comparison of
males vs. females. In this regard, we found that average scores were significantly higher for
males than for females only for the procedural component (Table 3).
On the other hand, we compared the three components -conceptual, procedural and attitu-
dinal- using the ANOVA test. Results showed statistical differences among the three compo-
nents, with all comparisons being statistically significant (p<0.00017): conceptual vs.
procedural, conceptual vs. attitudinal and procedural vs. attitudinal (Fig 1A).
Second, we analyzed the topics. Analysis of the topics in the conceptual component showed
the highest scores for the “Cell and tissue basis of the human body” topic, whereas the lowest
scores were found for the “Regulatory framework” topic (Table 2 and Fig 1B). Table 2 shows
the statistical p values for the ANOVA test for males vs. females. No gender differences were
found.
When each of the 5 topics in the conceptual component was compared with the other topics
in this component, the differences were statistically significant (p<0.00017) for all compari-
sons (Fig 1B).
For the procedural component, the highest scores were found for the “Biofabrication com-
ponents for advanced therapies” topic, whereas the lowest were found for “Centers for biofab-
rication and storage of advanced therapies” (Table 3 and Fig 1B). For gender comparisons, we
found that males assigned higher scores than females in items under the “Biofabrication com-
ponents for advanced therapies” topic (statistically significant differences) (Table 3).
Pairwise comparisons of these topics revealed statistically significant differences
(p<0.00017) for all comparisons except “Application and use of advanced therapies” vs. “Bio-
fabrication components for advanced therapies”, and “Application and use of advanced thera-
pies” vs. “Application center for advanced therapies”, which were nonsignificant (Fig 1B).
When topics included in the attitudinal component were analyzed, we found that the high-
est scores corresponded to the “Valuation of treatment with advanced therapies” topic, while
the lowest scores were found for “Valuation of centers for advanced therapies” (Table 4 and
Fig 1B). No differences were observed between males and females for any of the topics
(Table 4).
Pairwise comparisons between specific topics in this component yielded statistically signifi-
cant differences (p<0.00017) among all topics, except for the comparison between “Research
interest in advanced therapies” vs. “Research interest in classical therapies” (Fig 1B).
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Third, we analyzed the results for each specific item. Averages and standard deviations for
each item are shown in Table 2, whereas the statistical p values for the comparison of two spe-
cific items are shown in Table 5. In the conceptual component (Fig 2A), we did not found any
significant differences between male residents and female residents. For the “Advanced thera-
pies” topic, the highest scores were given to item AdT2 “Are you familiar with the concept of
gene therapy?”, which showed statistically significant differences (p<0.00017) compared to the
rest of the items in this topic (Table 5). In contrast, items AdT3 “Are you familiar with the
Table 2. Mean values and standard deviations (SD) for the conceptual component and for each topic and each item included in this component. In each case, results
are shown for male and female residents separately and for all residents together. The last column shows the statistical p value for ANOVA comparisons between genders.















CONCEPTUAL Advanced therapies AdT1 2.86 1.31 2.68 1.20 2.73 1.23 0.252
AdT2 3.71 1.06 3.39 1.18 3.48 1.16 0.031
AdT3 2.54 1.23 2.16 1.14 2.26 1.18 0.012
AdT4 2.27 1.20 2.15 1.09 2.18 1.12 0.424
AdT5 2.77 1.33 2.72 1.34 2.74 1.33 0.764
AdT6 2.68 1.27 2.77 1.33 2.74 1.32 0.596
ALL 2.81 1.31 2.64 1.29 2.69 1.29 0.019
Artificial tissues ArT1 3.46 1.22 3.56 1.20 3.53 1.20 0.556
ArT2 3.23 1.26 3.13 1.23 3.15 1.24 0.526
ArT3 4.07 0.90 3.88 0.98 3.93 0.96 0.121
ArT4 3.58 1.08 3.51 1.16 3.53 1.14 0.636
ArT5 3.07 1.26 3.10 1.22 3.09 1.23 0.871
ArT6 3.36 1.24 3.09 1.23 3.16 1.24 0.090
ALL 3.46 1.20 3.38 1.21 3.40 1.21 0.176
Cell and tissue basis of
the human body
CTB1 4.55 0.72 4.65 0.68 4.62 0.69 0.258
CTB2 4.54 0.68 4.64 0.65 4.61 0.66 0.223
CTB3 4.44 0.83 4.52 0.74 4.50 0.77 0.429
CTB4 4.04 1.05 3.97 1.05 3.99 1.05 0.638
CTB5 3.68 1.26 3.58 1.14 3.61 1.17 0.529
CTB6 2.00 1.18 1.79 1.07 1.85 1.10 0.134
ALL 3.87 1.32 3.86 1.35 3.86 1.34 0.830
Novel medical products NMP1 2.95 1.21 3.09 1.25 3.05 1.24 0.379
NMP2 3.02 1.23 3.06 1.25 3.05 1.24 0.843
NMP3 2.87 1.27 2.76 1.24 2.79 1.24 0.512
NMP4 3.63 1.20 3.37 1.29 3.44 1.27 0.110
NMP5 4.11 0.96 4.06 1.09 4.08 1.06 0.756
NMP6 2.60 1.35 2.67 1.26 2.65 1.28 0.666
ALL 3.20 1.31 3.17 1.31 3.18 1.31 0.690
Regulatory framework RF1 1.98 1.20 1.99 1.17 1.99 1.18 0.924
RF2 1.62 1.00 1.34 0.77 1.42 0.85 0.010
RF3 1.61 0.98 1.31 0.72 1.40 0.81 0.005
RF4 2.82 1.41 2.77 1.41 2.78 1.41 0.771
RF5 2.65 1.41 2.57 1.38 2.60 1.39 0.652
RF6 2.24 1.26 2.06 1.18 2.11 1.20 0.263
ALL 2.15 1.30 2.01 1.26 2.05 1.28 0.034
CONCEPTUAL
COMPONENT
3.10 1.42 3.01 1.43 3.04 1.43 0.009
https://doi.org/10.1371/journal.pone.0214950.t002
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concept of somatic cell therapy?” and AdT4 “Are you familiar with the concept of combined
advanced therapy?” received significantly lower scores than the remaining items under this
topic. For the “Artificial tissues” topic we found the highest score for item ArT3 “Are you
familiar with the concept of growth factors?”, which was significantly higher than the remain-
ing item scores, whereas ArT2 “Are you familiar with the concept of biomaterial?”, ArT5 “Are
you familiar with the concept of tissue engineering?” and ArT6 “Are you familiar with the con-
cept of regenerative medicine?” had the lowest scores. For the “Cell and tissue basis of the
human body” topic, items CTB1 “Are you familiar with the concept of cell?” and CTB2 Are
you familiar with the concept of tissue?” had the highest scores of all items in this topic and in
the conceptual component overall. However, item CTB6 “Are you familiar with the concept of
IPS cell?” scored significantly lower than the remaining items in this topic. For the “Novel
medical products” topic, item NMP5 “Do you know if growth factors are used to treat
Table 3. Mean values and standard deviations (SD) for the procedural component and for each topic and each item included in this component. In each case, results
are shown for male and female residents separately and for all residents together. The last column shows the statistical p value for ANOVA comparisons between genders.















PROCEDURAL Application and use of
advanced therapies
AUAT1 4.42 0.98 4.38 0.77 4.39 0.84 0.699
AUAT2 3.95 1.21 3.93 0.96 3.93 1.03 0.842
AUAT3 4.32 0.82 4.27 0.80 4.28 0.80 0.609
AUAT4 4.38 0.85 4.24 0.82 4.28 0.83 0.173
AUAT5 4.43 0.80 4.28 0.75 4.32 0.77 0.126
AUAT6 4.17 0.94 4.10 0.94 4.12 0.94 0.592
ALL 4.28 0.96 4.20 0.85 4.22 0.88 0.100
Application center for
advanced therapies
ACAT1 4.33 0.83 4.26 0.75 4.28 0.77 0.486
ACAT2 4.04 1.21 3.93 1.07 3.96 1.11 0.462
ACAT3 4.33 0.83 4.25 0.84 4.27 0.84 0.440
ACAT4 3.99 1.28 3.85 1.14 3.89 1.18 0.355
ACAT5 4.35 0.84 4.26 0.81 4.28 0.82 0.413
ACAT6 3.98 1.26 3.92 1.06 3.94 1.12 0.703
ALL 4.17 1.07 4.08 0.97 4.10 1.00 0.101
Biofabrication components
for advanced therapies
BCAT1 4.51 0.75 4.40 0.79 4.43 0.78 0.260
BCAT2 4.55 0.65 4.34 0.77 4.40 0.74 0.029
BCAT3 4.40 0.79 4.13 0.99 4.21 0.95 0.026
BCAT4 4.30 0.85 4.06 1.03 4.12 0.99 0.057
BCAT5 4.25 0.88 4.12 0.99 4.15 0.96 0.279
BCAT6 4.23 0.91 4.13 0.99 4.15 0.97 0.416
ALL 4.37 0.81 4.19 0.94 4.24 0.91 7.08E-05�
Centers for biofabrication
and storage of advanced
therapies
CBSAT1 4.38 0.83 4.29 0.81 4.32 0.82 0.396
CBSAT2 4.43 0.70 4.28 0.82 4.32 0.79 0.149
CBSAT3 4.15 1.00 4.13 0.96 4.13 0.97 0.812
CBSAT4 3.80 1.17 3.60 1.15 3.65 1.15 0.177
CBSAT5 3.05 1.43 2.72 1.23 2.81 1.30 0.047
CBSAT6 4.27 0.91 4.23 0.86 4.24 0.88 0.708
ALL 4.01 1.14 3.87 1.14 3.91 1.14 0.020
PROCEDURAL
COMPONENT
4.21 1.01 4.09 0.99 4.12 1.00 3.89E-06�
Statistically significant values (p<0.00017) are highlighted with asterisks (�).
https://doi.org/10.1371/journal.pone.0214950.t003
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diseases?” scored significantly higher than the other items, whereas NMP6 “Do you know if
there are benefits of these therapies with respect to current treatment techniques?” and NMP3
“Do you know if transplanted organs are medicines?” had the lowest scores. Regarding the
Table 4. Mean values and standard deviations (SD) for the attitudinal component and for each topic and each item included in this component. In each case, results
are shown for male and female residents separately, and for all residents together. The last column shows the statistical p value for ANOVA comparisons between genders.















ATTITUDINAL Research interest in
advanced therapies
RIAT1 3.85 1.20 3.83 1.05 3.83 1.09 0.907
RIAT2 3.90 1.16 3.86 1.07 3.87 1.09 0.732
RIAT3 3.92 1.16 3.79 1.09 3.82 1.11 0.364
RIAT4 4.25 0.92 4.23 0.76 4.23 0.80 0.823
RIAT5 4.33 0.84 4.17 0.82 4.21 0.83 0.119
RIAT6 4.36 0.90 4.11 0.91 4.18 0.91 0.036
ALL 4.10 1.06 4.00 0.97 4.03 1.00 0.053
Research interest in
classical therapies
RICT1 3.65 1.32 3.63 1.25 3.64 1.27 0.878
RICT2 3.81 1.21 3.77 1.08 3.78 1.12 0.776
RICT3 3.69 1.28 3.84 1.07 3.80 1.13 0.311
RICT4 3.70 1.21 4.00 1.04 3.91 1.09 0.037
RICT5 4.29 0.95 4.18 0.85 4.21 0.88 0.352
RICT6 4.21 0.97 4.22 0.81 4.22 0.86 0.943
ALL 3.89 1.19 3.94 1.05 3.93 1.09 0.445
Valuation of centers for
advanced therapies
VCAT1 3.81 1.04 3.74 1.05 3.76 1.04 0.609
VCAT2 3.90 1.03 3.86 1.02 3.87 1.02 0.740
VCAT3 3.87 0.98 3.86 1.00 3.86 1.00 0.922
VCAT4 3.90 0.99 3.83 0.99 3.85 0.99 0.552
VCAT5 3.69 1.13 3.62 1.11 3.64 1.12 0.604
VCAT6 2.54 1.29 2.30 1.18 2.37 1.22 0.133
ALL 3.62 1.18 3.53 1.20 3.56 1.19 0.172
Valuation of treatment
with advanced therapies
VTAT1 4.29 0.82 4.32 0.79 4.31 0.80 0.709
VTAT2 4.12 1.03 4.25 0.84 4.21 0.90 0.273
VTAT3 4.32 0.75 4.27 0.84 4.29 0.82 0.646
VTAT4 4.10 1.03 4.05 0.96 4.06 0.98 0.698
VTAT5 4.35 0.80 4.33 0.76 4.33 0.77 0.868
VTAT6 4.31 0.73 4.28 0.81 4.29 0.78 0.753
ALL 4.25 0.87 4.25 0.84 4.25 0.85 0.944
ATTITUDINAL
COMPONENT
3.96 1.11 3.93 1.05 3.94 1.07 0.220
https://doi.org/10.1371/journal.pone.0214950.t004
Fig 1. Boxplots of the results for the components and topics analyzed in this study. A: Components. B: Topics.
Statistically significant differences (p<0.00017) are labeled with asterisks (�).
https://doi.org/10.1371/journal.pone.0214950.g001
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“Regulatory framework” topic, items RF4 “Do you know if it is mandatory to perform a clini-
cal trial before using advanced therapy products?” and RF5 “Do you know if all advanced ther-
apies require authorization from the Spanish and European agencies for their
implementation?” received significantly higher scores than the other items, whereas the lowest
scores were found for RF2 “Do you know what GMP rooms are?” and RF3 “Do you know if it
is mandatory to manufacture advanced therapy products considered medicines in GMP
rooms?”.
Analysis of the items in the procedural component (Fig 2B) disclosed some significant dif-
ferences. Averages and standard deviations for each item are shown in Table 3, and the statisti-
cal p values for the comparison of two specific items are shown in Table 6. When males and
females were compared, we did not found any significant differences. In the “Application and
use of advanced therapies” topic, item AUAT1 “Would you use the patient’s own cells for
treatment with cell therapy?” scored significantly higher (p<0.00017; Table 6) than item
AUAT2 “Would you use cells from donors to treat a patient with cell therapy?”. Item AUAT2
“Would you use cells from donors to treat a patient with cell therapy?” scored significantly
lower than AUAT3 “Would you apply cell therapy to treat a disease?”, AUAT4 “Would you
apply gene therapy to treat a disease?” and AUAT5 “Would you apply tissue-engineered tissues
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Statistically significant values (p<0.00017) are highlighted with asterisks (�).
https://doi.org/10.1371/journal.pone.0214950.t005
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to treat a disease?”. Regarding the “Application center for advanced therapies” topic, the three
items that mentioned hospitals, e.g. ACAT1 “Would you use hospitals for a cell therapy treat-
ment?”, ACAT3 “Would you use hospitals for a gene therapy treatment?” and ACAT5 “Would
you use hospitals to treat a patient with artificial tissues generated by tissue engineering?”
received significantly higher scores than the three items on advanced therapies in primary care
health centers (ACAT2, ACAT4 and ACAT6). For the “Biofabrication components for
advanced therapies” topic, the highest scores were found for items BCAT1 “Would you use
umbilical cord stem cells to build artificial tissues?” and BCAT2 “Would you use bone marrow
stem cells to build artificial tissues?”. The differences were statistically significant for the com-
parison between the first of these items and BCAT4 “Would you use dental pulp stem cells to
build artificial tissues?”, BCAT5 “Would you build artificial tissues with biomaterials?” and
BCAT6 “Would you build artificial tissues with growth factors?”. In addition, the difference
between BCAT2 “Would you use bone marrow stem cells to build artificial tissues?” and
BCAT4 “Would you use dental pulp stem cells to build artificial tissues?” was statistically
Fig 2. Boxplots of the results for the items included in each topic. A: Items in the conceptual component. B: Items in
the procedural component. C: Items in the attitudinal component.
https://doi.org/10.1371/journal.pone.0214950.g002
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significant. For the “Centers for biofabrication and storage of advanced therapies” topic, items
CBSAT1 “Would you store artificial tissues in tissue banks for deferred use?”, CBSAT2
“Would you store cells in tissue banks for deferred use?” and CBSAT6 “Would you use a
research center to build artificial tissues?” obtained the highest scores, whereas CBSAT5
“Would you use a pharmaceutical company to build artificial tissues?” scored lowest of all
items across all procedural topics. The differences were statistically significant for, among oth-
ers, the comparisons of item CBSAT5 “Would you use a pharmaceutical company to build
artificial tissues?”, which received the lowest score, and CBSAT4 “Would you use a primary
care health center to build artificial tissues?” vs. the remaining items.
Finally, in the attitudinal component (Fig 2C), we did not found significant differences
between the scores given by males and females (Table 4). Averages and standard deviations for
each item are shown in Table 4, and the statistical p values for the comparison of two specific
items are shown in Table 7. For the “Research interest in advanced therapies” topic, the highest
scores were found for items RIAT4 “Do you think performing clinical trials in cell therapy is a
good idea?”, RIAT5 “Do you think performing clinical trials with artificial tissues is a good
idea?” and RIAT6 “Do you think performing clinical trials in gene therapy is a good idea?”,
and some differences compared to the other items in this topic were statistically significant
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Statistically significant values (p<0.00017) are highlighted with asterisks (�).
https://doi.org/10.1371/journal.pone.0214950.t006
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(p<0.00017; Table 7). Analysis of the “Research interest in classical therapies” topic showed
that items RICT5 “Do you think performing clinical trials to test pharmaceutical drugs is a
good idea?” and RICT6 “Do you think performing clinical trials in physical therapy is a good
idea?” had the highest scores, with significant differences compared to most of the remaining
items, whereas the lowest values were seen for item RICT1 “Are you interested in research in
surgery?”. Regarding the “Valuation of centers for advanced therapies” topic, we found that
items VCAT2 “Do you prefer hospitals for the application of gene therapy?”, VCAT3 “Do you
prefer hospitals for the application of artificial tissue therapy?” and VCAT4 “Do you prefer
hospitals for the application of combined advanced therapies?” received the highest scores,
whereas VCAT6 “Do you prefer artificial tissues to be manufactured by the pharmaceutical
industry?” had the lowest item score across all attitudinal topics, with significant differences
compared to the rest of the items. In the last attitudinal topic, “Valuation of treatment with
advanced therapies”, most items received similarly high scores, whereas item VTAT4 “Do you
think so-called advanced therapies are a good idea?” had the lowest score.
Discussion
The increasing relevance of gene-, cell- and tissue-based therapies in medicine and the expec-
tations these novel therapies generate in the population of health care users require specific
Table 7. Statistical p values for pairwise comparisons of two specific items included in each topic of the attitudinal component.
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https://doi.org/10.1371/journal.pone.0214950.t007
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studies in this field. Incorporating knowledge about advanced therapies in training programs
for future family medicine physicians will allow these professionals to contribute effectively to
health education in the user population. However, before training activities are developed and
implemented for family medicine residents, their conceptual, procedural and attitudinal pro-
files related to these therapies should be investigated. As indicated by different theoretical
frameworks in educational research, a wide range of circumstances can potentially promote or
limit the learning process in a particular situation [20–22]. Moreover, studies of medical resi-
dents’ perceptions regarding professional practice have demonstrated the importance that resi-
dents give to the need to overcome shortcomings in their professional behavior, cognitive
ability and procedure skills [23, 24].
In the present study we examined how family medicine residents perceive advanced thera-
pies in terms of their knowledge, their approach to implementing these therapies, and their
attitudes toward these novel therapeutic tools. According to the overall results of this study,
the scores for the procedural component were the highest among the three components of per-
ception in family medicine residents, whereas the lowest scores were found for the conceptual
component. Strikingly, although residents perceived that procedures for implementing
advanced therapies are well established, probably due to the strict regulation of protocols [1,
25], they also perceived that their cognitive background is insufficient to respond to the expec-
tations generated by these new therapeutic tool.
The scores for the attitudinal component were intermediate between the procedural and
conceptual components. Attitudes represent a summation of thinking, emotions and feelings
about a specific issue–for example, in the context of learning a course [19]. This facilitates not
only personal equilibrium, but also the positive coexistence of professional and social values
and beliefs. As pointed out by Li et al. [26], the current literature lacks a discussion of the atti-
tudes of the medical community regarding ways to balance cost-effectiveness with equity in
the use of and access to treatments. Our results reflect this situation. In fact, the attitudes of
family medicine residents who participated in the present study are situated in a prudent bal-
ance between what they perceive could be implemented clinically–the procedural component–
and what they perceive they know about advances therapies–the conceptual component.
When we analyzed the different topics included in the conceptual component, our results
highlighted that residents gave the highest values to their perceived knowledge of cells and tis-
sues in the human body, and the lowest values to their knowledge of the regulatory framework
for these therapies. After knowledge of cells and tissues, the perception of topics regarding
knowledge of artificial tissues, advanced therapies and new medical products received progres-
sively lower scores. These results may be explained by the fact that most of the topics and items
our respondents scored highest correspond to concepts that are part of the core curriculum of
medical training in medical schools [20, 27], in contrast with other concepts such as GMP
facilities, IPs cells or biomaterials. In addition, these findings may have been influenced by the
widespread use of growth factors among commonly used advanced therapies [28–30], the
wide dissemination of news about gene therapy in the lay media [31, 32], and finally, the appli-
cation to advanced therapies of regulations and protocols that residents are usually familiar
with for ordinary therapies (e.g. clinical trials, authorizations, etc.) [33, 34].
Regarding the topics and items included in the procedural component, the highest and low-
est scores were found, respectively, for "biofabrication components for advances therapies"
and "centers for biofabrication and storage of advances therapies”. In the former case, there
was good correlation with the results for the conceptual component, since the topic with the
highest score in this component (knowledge of cells and tissues) constitutes the foundation of
knowledge elements that are needed for the biofabrication of ATMPs [1, 25]. In the latter case,
procedural knowledge referred to centers for the manufacture and storage of advanced
Advanced therapies in family medicine
PLOS ONE | https://doi.org/10.1371/journal.pone.0214950 April 3, 2019 14 / 19
therapies is mostly absent from the training objectives for family medicine residents. These
results show that residents are better informed about the procedures needed to apply advanced
therapies than about the types of center where each therapy should be applied. This is consis-
tent with the low scores obtained for knowledge of the regulatory framework in the conceptual
component, as discussed above. Spanish family medicine residents are willing to consider
advanced therapies as a possible tool in the therapeutic management of their patients. How-
ever, as deduced from their responses, they seem highly aware of the risks and limitations,
given that they indicated their preference for using tools that have been well tested in clinical
research, e.g. stem cells from the bone marrow or umbilical cord, and would prefer to use
autologous cells instead of donor cells. Nevertheless, this situation is likely to change in the
immediate future because some stem cells, which can be cryopreserved and stored in tissue
banks, are increasingly used in advanced therapies to treat a variety of oncologic, genetic,
hematologic and immune deficiency disorders [35–38]. This means that in the foreseeable
future, family medicine physicians will come to play an important role not only in patients’
education–i.e., how to guide patients contemplating unproven and unapproved advanced
therapies, and thus avoid medical tourism–but also in patients’ safety at the primary care level,
in the daily follow-up of patients treated with this type of therapy [39]. Although some authors
have expressed alarm over the decrease in the scope of care being provided by family medicine
physicians, the emergence of advances therapies opens new areas of activity within the remit
of these professionals–activities, however, that the residents in this study did not seem to sig-
nificantly perceive at the present time [27, 40, 41].
When topics and items of the attitudinal component were analyzed, we found that the high-
est scores corresponded to valuation of treatment with advanced therapies, while the lowest
scores were seen for valuation of centers where these therapies would be implemented. Again,
and in consonance with the tendency observed for the procedural component, residents’ atti-
tude-related responses attributed more value to the possible use of these new treatments than
to the logistic support that makes these treatments possible. However, they expressed a prefer-
ence for hospitals as the most appropriate setting for the application of advanced therapies,
and were less supportive of the manufacture of artificial tissues as medical products by the
pharmaceutical industry. In addition, residents valued research in advanced therapies more
highly than research in classical therapies. Although it has been suggested that family medicine
residents are less interested in research than other graduates, our results showed that they not
only had a positive attitude towards new therapies, but also expressed a more favorable attitude
towards research in new therapies than towards research in classical therapies [42, 43]. The
attitudes reported by the residents in our sample again showed that they are aware of the need
to use proven therapeutic tools for both classical and advanced therapies. This finding argues
very strongly in favor of efforts to involve family medicine physicians in health education pro-
grams for these new therapies. Family medicine professionals should act as qualified medical
educators able to guide patients regarding proven and unproven advanced interventions, and
to advise patients on cost-effectiveness in the use of and access to treatments [26, 40, 41, 44,
45].
Regarding gender, our results showed very few differences between male and female resi-
dents. Significant differences were found only for the procedural component and for the “Bio-
fabrication components for advanced therapies” topic, but not for the conceptual and
attitudinal components. These findings are consistent with the patterns usually described in
relation to gender and medicine [15, 46–48]. Our results can contribute to a better under-
standing of residents’ profiles regarding advanced therapies, and the slight gender differences
detected in our respondents should be taken into account when new training programs are
implemented in this area. Although differences between genders remain poorly understood,
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they may result from factors such as role modeling and socialization by family, teachers, peers
and the media, rather than from “innate or natural differences” between women and men [48,
49].
In conclusion, this questionnaire-based study provides evidence that can be used to estab-
lish profiles associated with the conceptual, procedural and attitudinal components of Spanish
family medicine residents’ views on advanced therapies. Although they perceived that proce-
dures to implement advanced therapies are well established, especially in terms of application,
they feel their cognitive background is not strong enough to efficiently respond to the expecta-
tions generated by these new therapeutic tools, and perceive themselves to be especially under-
prepared regarding their knowledge of the regulatory framework. In their attitudinal
responses, residents gave more value to the possible use of these new treatments than to the
logistic support that makes these new therapies possible, and on a secondary level, they also
gave more value to research in advanced therapies than in classical therapies. Their keen
awareness of the risks and limitations of these treatments was reflected by their preference for
using cells that have undergone thorough clinical testing. Although they appropriately situated
treatment with these therapies at the hospital level, it is important to note that they signifi-
cantly associated biofabrication with research centers, although these therapeutic tools can
also be produced at different types of facilities.
One of the limitations of this study is the use of a questionnaire designed and validated orig-
inally in the Spanish language. Although the most relevant concepts are accurately translatable
into English, care should be exercised before using the translated questionnaire for native
English speakers, since some items may not perfectly match the answers provided by the
Likert-like scale used here. Future work should aim to ensure the accurate translation and cul-
tural adaptation of the questionnaire for respondents in specific settings. Versions of the ques-
tionnaire in other languages should be used only after an appropriately validated translation
process. Another limitation is the use of the same response scale for all conceptual, procedural
and attitudinal items, some of which may require specific answer options. However, using the
same scale favored homogeneity and comparability among the items, topics and components.
Despite these limitations, we conclude that the results of this study are potentially useful to
support the design of future training programs and health policies of family medicine resi-
dents, in view of the rapid development of these treatments, the expectations they raise in
patients, and the responsibility of professionals to use these complex therapies in an equitable
and cost-effective manner.
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